

Table S1. Summary of new starts for first- through seventh-lines of therapy included in the current analyses; patients with psoriatic arthritis initiating new therapy during the registry

	<u>Ustekinumab</u>	<u>Infliximab</u>	<u>Adalimumab</u>	<u>Etanercept</u>	<u>Total</u>
New Therapy Starts, N	240	73	152	74	539
First-Line Therapy ^a	41 (17.1)	20 (27.4)	33 (21.7)	25 (33.8)	119
Second-Line Therapy	63 (26.3)	18 (24.7)	84 (55.3)	27 (36.5)	192
Third-Line Therapy	82 (34.2)	19 (26.0)	22 (14.5)	18 (24.3)	141
Fourth-Line Therapy	39 (16.3)	12 (16.4)	12 (7.9)	3 (4.1)	66
Fifth-Line Therapy	10 (4.2)	2 (2.7)	1 (0.7)	1 (1.4)	14
Sixth-Line Therapy	5 (2.1)	2 (2.7)	0	0	7
Seventh-Line Therapy	0	0	0	0	0

Data are presented as number of patients (%).

^aFor both second- and third-lines of therapy beyond first-lines, the prior biologic may have been any of the four biologics included in these analyses or other biologics not approved for psoriasis (golimumab), those no longer available for treating psoriasis (efalizumab and alefacept), or those received via participation in a clinical study but not available for treatment of psoriasis (briakinumab).